2026-09-25T11:35:44Zhttps://dspace.mit.edu/server/oai/requestoai:dspace.mit.edu:1721.1/1187402022-01-13T07:54:05Zcom_1721.1_7582com_1721.1_7581col_1721.1_131023
Luis Fernando Velásquez-García.
Beckwith, Ashley L. (Ashley Lynne)
Massachusetts Institute of Technology. Department of Mechanical Engineering.
Massachusetts Institute of Technology. Department of Mechanical Engineering
2018-10-22T18:47:12Z
2018-10-22T18:47:12Z
2018
2018
http://hdl.handle.net/1721.1/118740
1057285927
Thesis: S.M., Massachusetts Institute of Technology, Department of Mechanical Engineering, 2018.
Cataloged from PDF version of thesis.
Includes bibliographical references (pages 61-65).
This thesis presents the development of an entirely 3D-printed, monolithic microfluidic platform for evaluating the efficacy of immunotherapy treatments. The platform provides a dynamic microenvironment for perfusing and sustaining tumor samples extracted from a biopsy. The finely featured, non-cytotoxic, and transparent tumor trap is integrated with threaded connectors for rapid, leak-proof fluid interfacing, an in-line trap for removal of bubbles arising from oxygenated media flow or tumor loading procedures, and a network of microchannels for supplying media and immunotherapies to a retained tumor fragment. The device configuration is capable of modelling interactions between tumors and various drug treatments. Tested devices were additively manufactured in Pro3dure GR-10 -a relatively new, high-resolution stereolithographic resin with properties suitable for biomedical applications. Retention of human tumor fragments within the printed microfluidic device is confirmed through overlaid bright-field and fluorescence micrographs, which permit visualization of individual tumor cells within the biological sample. Under dynamic perfusion of media, live tumor fragments can be sustained for a period of at least 72 hours. Confocal microscopy confirmed that sustained tumors and the resident lymphocytes exhibited a response to perfused immunotherapy treatments compared to an untreated control. With further validation, the proposed platform may be capable of providing critical predictive insight into an individual's response to selected immunotherapies.
by Ashley L. Beckwith.
S.M.
65 pages
eng
Massachusetts Institute of Technology
MIT theses are protected by copyright. They may be viewed, downloaded, or printed from this source but further reproduction or distribution in any format is prohibited without written permission.
http://dspace.mit.edu/handle/1721.1/7582
Mechanical Engineering.
Additive manufacturing of microfluidics for evaluation of immunotherapy efficacy
Thesis
application/pdf
Publication
unknown
unknown
<Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="b501ed81-3f45-4efb-b7d2-b2f002025fc5">
<Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843</Type>
<Language>eng</Language>
<Title>Additive manufacturing of microfluidics for evaluation of immunotherapy efficacy</Title>
<PublishedIn>
<Publication>
</Publication>
</PublishedIn>
<PublicationDate>2018</PublicationDate>
<Authors>
<Author>
<DisplayName>Beckwith, Ashley L. (Ashley Lynne)</DisplayName>
<Affiliation>
<OrgUnit>
</OrgUnit>
</Affiliation>
</Author>
</Authors>
<Editors>
</Editors>
<Publishers>
<Publisher>
<DisplayName>Massachusetts Institute of Technology</DisplayName>
<OrgUnit />
</Publisher>
</Publishers>
<License>http://dspace.mit.edu/handle/1721.1/7582</License>
<Keyword>Mechanical Engineering.</Keyword>
<Abstract>This thesis presents the development of an entirely 3D-printed, monolithic microfluidic platform for evaluating the efficacy of immunotherapy treatments. The platform provides a dynamic microenvironment for perfusing and sustaining tumor samples extracted from a biopsy. The finely featured, non-cytotoxic, and transparent tumor trap is integrated with threaded connectors for rapid, leak-proof fluid interfacing, an in-line trap for removal of bubbles arising from oxygenated media flow or tumor loading procedures, and a network of microchannels for supplying media and immunotherapies to a retained tumor fragment. The device configuration is capable of modelling interactions between tumors and various drug treatments. Tested devices were additively manufactured in Pro3dure GR-10 -a relatively new, high-resolution stereolithographic resin with properties suitable for biomedical applications. Retention of human tumor fragments within the printed microfluidic device is confirmed through overlaid bright-field and fluorescence micrographs, which permit visualization of individual tumor cells within the biological sample. Under dynamic perfusion of media, live tumor fragments can be sustained for a period of at least 72 hours. Confocal microscopy confirmed that sustained tumors and the resident lymphocytes exhibited a response to perfused immunotherapy treatments compared to an untreated control. With further validation, the proposed platform may be capable of providing critical predictive insight into an individual's response to selected immunotherapies.</Abstract>
<Access xmlns="http://purl.org/coar/access_right"
>
</Access>
</Publication>